NOVAVAX, INC. (NASDAQ:NVAX) Files An 8-K Submission of Matters to a Vote of Security Holders

NOVAVAX, INC. (NASDAQ:NVAX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.

The Annual Meeting of Stockholders of Novavax, Inc. (the “Company”) was held on June 28, 2019 (the “Annual Meeting”). Only stockholders of record as of May 2, 2019 (the “Record Date”) were entitled to vote at the Annual Meeting. As of the Record Date, there were 469,453,883 shares of common stock, par value $0.01 (the “Common Stock”) outstanding and entitled to vote at the Annual Meeting. After giving effect to the 1-for-20 reverse split of the Company’s issued and outstanding shares of Common Stock, effected on May 10, 2019 to the Certificate of Amendment to the Company’s Second Amended and Restated Certificate of Incorporation dated May 8, 2019 (the “1-for-20 Reverse Stock Split”), and before giving effect to the cancellation of fractional shares in connection therewith, on the Record Date, 23,472,694 shares of Common Stock would have been outstanding and entitled to vote at the Annual Meeting, of which 16,693,045 shares were represented by proxy, constituting a quorum on all matters voted upon. All references to a number of shares of Common Stock presented in the remainder of this Current Report reflect the 1-for-20 Reverse Stock Split. The final voting results of the Annual Meeting are as follows:

Proposal 1: Stockholders elected the following Class III nominees for director, each to serve until the 2022 Annual Meeting of Stockholders or until his successor is duly elected and qualified:

15,076,480 1,377,930 238,635


Story continues below

Novavax, Inc. (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. Its product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). Its lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

An ad to help with our costs